Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial-Reference-Cited by-同舟云学术

Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial

Published:2022-05 Issue:2 Volume:303 Page:455-464
ISSN:0033-8419
Container-title:Radiology
language:en
Short-container-title:Radiology

Author:

Zheng Kanglian¹^ORCID,Zhu Xu¹,Fu Shijie¹,Cao Guang¹,Li Wen-Qing¹^ORCID,Xu Liang¹,Chen Hui¹,Wu Di¹,Yang Renjie¹,Wang Kun¹,Liu Wei¹,Wang Hongwei¹^ORCID,Bao Quan¹,Liu Ming¹,Hao Chunyi¹,Shen Lin¹^ORCID,Xing Baocai¹,Wang Xiaodong¹^ORCID

Affiliation:

1. From the Departments of Interventional Oncology (K.Z., X.Z., S.F., G.C., L.X., H.C., D.W., R.Y., X.W.), Cancer Epidemiology (W.Q.L.), Hepatic and Biliary Surgery (K.W., W.L., H.W., Q.B., M.L., C.H., B.X.), and Gastrointestinal Oncology (L.S.), Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing 100142, China.

Funder

Clinical Medicine Development of Special Funding Support

Beijing Natural Science Foundation

National Natural Science Foundation of China

Publisher

Radiological Society of North America (RSNA)

Subject

Radiology, Nuclear Medicine and imaging

Link

http://pubs.rsna.org/doi/pdf/10.1148/radiol.211545

Reference32 articles.

1. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials